Shen, Qi
Jin, Ying https://orcid.org/0000-0002-4934-7350
Di, Xiangjie https://orcid.org/0000-0002-2259-372X
Hu, Chao
Liu, Runhan https://orcid.org/0000-0002-9385-8350
Wang, Ying
Qi, Xiaohui
Wang, Yongsheng
Wang, Zhenlei https://orcid.org/0000-0001-8789-4219
Funding for this research was provided by:
Youth Program of National Natural Science Foundation of China (81903722)
Article History
Accepted: 25 May 2022
First Online: 21 June 2022
Change Date: 22 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40261-023-01321-3
Declarations
:
: This study was sponsored by China Novartis Institutes for Biomed. Research Co., Ltd., (Shanghai, China). This research was supported by the Youth Program of National Natural Science Foundation of China (81903722).
: The authors have no conflicts of interest to declare.
: The clinical study protocol was approved by the Ethics Committee at the West China Hospital of Sichuan University (Chengdu, China). Clinical procedures were conducted in the Early Clinical Research Ward of Clinical Trial Center of West China Hospital of Sichuan University. The study was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Clinical Practice (Chinese Clinical Trial Registry: ChiCTR2000032435).
: All subjects received a detailed study description and gave their written informed consent before enrollment.
: Not applicable.
: The study is registered on Chinese Clinical Trial Registry (no. ChiCTR2000032435). The data supporting the study fundings are available from the author (Z.W.) upon reasonable request.
: Not applicable.
: QS conceived and conceptualized the design of this study. QS, RL, CH and YW performed the clinical investigation. QS, ZW, XD and XQ performed formal analysis of the data and pharmacokinetic analysis. ZW, QS and YJ completed the writing—original draft. All authors contributed to writing—review and editing.